Safety and Effectiveness of Lonasen Post-marketing Surveillance in Treatment of Chinese Schizophrenia Patients

Safety and Effectiveness of Blonanserin Post-marketing Surveillance in Treatment of Chinese Schizophrenia Patients

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100048734

Enrollment

Unknown

Registered

2021-07-15

Start date

2018-09-01

Completion date

Unknown

Last updated

2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Case series:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Schizophrenia Patients who begin to receive blonanserin

Exclusion criteria

Exclusion criteria: No exclusion criteria

Design outcomes

Primary

Measure	Time frame
The incidence of AE;	—

Secondary

Measure	Time frame
The incidence of EPS;The incidence of akathisia;Proportion of the combined medications for EPS at the end of treatment;Changes from baseline in body weight at the end of treatment;Changes from baseline in BPRS total score at the end of treatment;	—

Countries

China

Contacts

Public ContactChen Jindong

The Second Xiangya Hospital of Central South University

chenjindong@csu.edu.cn+86 0731-85295888

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026